Interaction Between Alzheimer's Disease and Cerebral Small Vessel Disease: A Review Focused on Neuroimaging Markers

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Sep 23

PMID 36142419

Authors

Si Eun Kim

Hee Jin Kim

Hyemin Jang

Michael W Weiner

Charles DeCarli

Duk L Na

Sang Won Seo

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is characterized by the presence of β-amyloid (Aβ) and tau, and subcortical vascular cognitive impairment (SVCI) is characterized by cerebral small vessel disease (CSVD). They are the most common causes of cognitive impairment in the elderly population. Concurrent CSVD burden is more commonly observed in AD-type dementia than in other neurodegenerative diseases. Recent developments in Aβ and tau positron emission tomography (PET) have enabled the investigation of the relationship between AD biomarkers and CSVD in vivo. In this review, we focus on the interaction between AD and CSVD markers and the clinical effects of these two markers based on molecular imaging studies. First, we cover the frequency of AD imaging markers, including Aβ and tau, in patients with SVCI. Second, we discuss the relationship between AD and CSVD markers and the potential distinct pathobiology of AD markers in SVCI compared to AD-type dementia. Next, we discuss the clinical effects of AD and CSVD markers in SVCI, and hemorrhagic markers in cerebral amyloid angiopathy. Finally, this review provides both the current challenges and future perspectives for SVCI.

Citing Articles

Imaging markers of cerebral small vessel disease are associated with Alzheimer's disease: a systematic review and meta-analysis.

Wu Q, Zhang J, Lei P, Zhu X, Huang C Front Aging Neurosci. 2025; 17:1498636.

PMID: 40071121 PMC: 11894735. DOI: 10.3389/fnagi.2025.1498636.

Investigating ocular biomarkers and differential diagnosis of Alzheimer's disease and vascular cognitive impairment based on multimodal imaging.

Jin Z, Chen X, Jiang C, Feng X, Shang K, Li J J Biomed Opt. 2024; 29(12):126003.

PMID: 39735398 PMC: 11672116. DOI: 10.1117/1.JBO.29.12.126003.

Total burden of cerebral small vessel disease predict subjective cognitive decline in patients with Parkinson's disease.

Qiu W, Hu W, Ge Y, Liu P, Zhao M, Lu H Front Aging Neurosci. 2024; 16:1476701.

PMID: 39649721 PMC: 11621090. DOI: 10.3389/fnagi.2024.1476701.

WMH Contributions to Cognitive Impairment: Rationale and Design of the Diverse VCID Study.

DeCarli C, Rajan K, Jin L, Hinman J, Johnson D, Harvey D Stroke. 2024; 56(3):758-776.

PMID: 39545328 PMC: 11850211. DOI: 10.1161/STROKEAHA.124.045903.

Cerebrovascular markers of WMH and infarcts in ADNI: A historical perspective and future directions.

Maillard P, Fletcher E, Carmichael O, Schwarz C, Seiler S, DeCarli C Alzheimers Dement. 2024; 20(12):8953-8968.

PMID: 39535353 PMC: 11667517. DOI: 10.1002/alz.14358.

References

Banerjee G, Kim H, Fox Z, Rolf Jager H, Wilson D, Charidimou A . MRI-visible perivascular space location is associated with Alzheimer's disease independently of amyloid burden. Brain. 2017; 140(4):1107-1116. DOI: 10.1093/brain/awx003. View

Barthel H, Sabri O . Florbetaben to trace amyloid-β in the Alzheimer brain by means of PET. J Alzheimers Dis. 2011; 26 Suppl 3:117-21. DOI: 10.3233/JAD-2011-0068. View

Shinohara M, Tachibana M, Kanekiyo T, Bu G . Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies. J Lipid Res. 2017; 58(7):1267-1281. PMC: 5496044. DOI: 10.1194/jlr.R075796. View

Cho H, Choi J, Hwang M, Kim Y, Lee H, Lee H . In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016; 80(2):247-58. DOI: 10.1002/ana.24711. View

Cummings J . The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials. Alzheimers Dement. 2018; 15(1):172-178. PMC: 6417790. DOI: 10.1016/j.jalz.2018.05.006. View

Gorelick P, Scuteri A, Black S, DeCarli C, Greenberg S, Iadecola C . Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011; 42(9):2672-713. PMC: 3778669. DOI: 10.1161/STR.0b013e3182299496. View

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

Mattsson-Carlgren N, Leuzy A, Janelidze S, Palmqvist S, Stomrud E, Strandberg O . The implications of different approaches to define AT(N) in Alzheimer disease. Neurology. 2020; 94(21):e2233-e2244. PMC: 7357296. DOI: 10.1212/WNL.0000000000009485. View

Aizenstein H, Nebes R, Saxton J, Price J, Mathis C, Tsopelas N . Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008; 65(11):1509-17. PMC: 2636844. DOI: 10.1001/archneur.65.11.1509. View

10.

Tariq S, Barber P . Dementia risk and prevention by targeting modifiable vascular risk factors. J Neurochem. 2017; 144(5):565-581. DOI: 10.1111/jnc.14132. View

11.

Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H . Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol. 2009; 65(6):650-7. DOI: 10.1002/ana.21696. View

12.

Kroth H, Oden F, Molette J, Schieferstein H, Capotosti F, Mueller A . Discovery and preclinical characterization of [F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer's disease and other tauopathies. Eur J Nucl Med Mol Imaging. 2019; 46(10):2178-2189. PMC: 6667408. DOI: 10.1007/s00259-019-04397-2. View

13.

Pascoal T, Therriault J, Benedet A, Savard M, Lussier F, Chamoun M . 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020; 143(9):2818-2830. DOI: 10.1093/brain/awaa180. View

14.

Seo S, Cho S, Park A, Chin J, Na D . Subcortical vascular versus amnestic mild cognitive impairment: comparison of cerebral glucose metabolism. J Neuroimaging. 2008; 19(3):213-9. DOI: 10.1111/j.1552-6569.2008.00292.x. View

15.

Marquez F, Yassa M . Neuroimaging Biomarkers for Alzheimer's Disease. Mol Neurodegener. 2019; 14(1):21. PMC: 6555939. DOI: 10.1186/s13024-019-0325-5. View

16.

Bennett R, Robbins A, Hu M, Cao X, Betensky R, Clark T . Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer's disease. Proc Natl Acad Sci U S A. 2018; 115(6):E1289-E1298. PMC: 5819390. DOI: 10.1073/pnas.1710329115. View

17.

Wolk D, Price J, Saxton J, Snitz B, James J, Lopez O . Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009; 65(5):557-68. PMC: 2828870. DOI: 10.1002/ana.21598. View

18.

Park J, Seo S, Kim C, Kim G, Noh H, Kim S . Pathogenesis of cerebral microbleeds: In vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment. Ann Neurol. 2013; 73(5):584-93. DOI: 10.1002/ana.23845. View

19.

Park J, Seo S, Kim C, Kim S, Kim G, Kim S . Effects of cerebrovascular disease and amyloid beta burden on cognition in subjects with subcortical vascular cognitive impairment. Neurobiol Aging. 2013; 35(1):254-60. PMC: 5849054. DOI: 10.1016/j.neurobiolaging.2013.06.026. View

20.

Terwel D, Muyllaert D, Dewachter I, Borghgraef P, Croes S, Devijver H . Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol. 2008; 172(3):786-98. PMC: 2258274. DOI: 10.2353/ajpath.2008.070904. View